IPN Stock Analysis: Ipsen | PA
Drug Manufacturers - Specialty & Generic | PA, France | Market Cap: 13.716m EUR | 12M Return: 53.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.8M
Qual. Beats: 0
Rev. Trend: 93.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ipsen S.A. is a France-based biopharmaceutical company founded in 1929 and headquartered in Paris. It develops and commercializes medicines across three therapeutic areas: oncology, rare disease, and neuroscience, with operations in North America, Europe, and other international markets. The company trades on Euronext Paris under the ticker IPN and is classified as a large-cap pharmaceutical issuer within the Health Care sector.
Ipsens marketed portfolio centers on specialty and rare-disease therapies. Key products include Somatuline for neuroendocrine tumors and acromegaly, Dysport for motor muscular disorders and medical aesthetics, Decapeptyl for prostate cancer and other hormone-responsive conditions, Cabometyx for renal cell carcinoma and related oncology indications, Onivyde for metastatic pancreatic cancer, and Bylvay for progressive familial intrahepatic cholestasis and Alagille syndrome. Several of these assets, notably Dysport and Decapeptyl, serve both therapeutic and elective or aesthetic demand.
The pipeline spans early- to late-stage clinical development. Late-stage programs include Iqirvo for primary biliary cholangitis, Sohonos for fibrodysplasia ossificans progressiva, Tazverik-based combinations in follicular lymphoma, and Tovorafenib in pediatric low-grade gliomas. Earlier-stage work covers IPN60340 in acute myeloid leukemia, multiple solid tumor candidates in Phase I, and IPN10200 across aesthetic and therapeutic indications.
As a European specialty pharmaceutical company, Ipsen follows a hybrid model combining proprietary development with in-licensed assets and targeted geographic expansion. Its focus on orphan indications, specialty oncology, and aesthetic medicine is a common mid-to-large-cap European pharma strategy, typically supported by premium pricing in rare diseases and partnership-driven commercialization in markets where the company lacks its own infrastructure.
- Somatuline generic erosion threatens neuroendocrine tumor franchise revenue
- Dysport aesthetics rebounds while therapeutics segment margins compress
- Cabometyx royalties and rare disease launches drive double-digit growth
| Net Income: 443.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 3.36 > 1.0 |
| NWC/Revenue: 37.66% < 20% (prev 14.43%; Δ 23.23% < -1%) |
| CFO/TA 0.16 > 3% & CFO 1.14b > Net Income 443.5m |
| Net Debt (-543.5m) to EBITDA (1.10b): -0.49 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.2m) vs 12m ago -1.57% < -2% |
| Gross Margin: 70.58% > 18% (prev 82.69%; Δ -12.11% > 0.5%) |
| Asset Turnover: 54.96% > 50% (prev 55.51%; Δ -0.55% > 0%) |
| Interest Coverage Ratio: 20.67 > 6 (EBIT TTM 746.3m / Interest Expense TTM 36.1m) |
| A: 0.20 (Total Current Assets 2.82b - Total Current Liabilities 1.44b) / Total Assets 6.94b |
| B: 0.06 (Retained Earnings 443.5m / Total Assets 6.94b) |
| C: 0.11 (EBIT TTM 746.3m / Avg Total Assets 6.69b) |
| D: 1.67 (Book Value of Equity 4.34b / Total Liabilities 2.60b) |
| Altman-Z'' = 4.02 = AA |
| DSRI: 1.30 (Receivables 932.1m/697.2m, Revenue 3.68b/3.57b) |
| GMI: 1.17 (GM 82.69% / 70.58%) |
| AQI: 0.85 (AQ_t 0.50 / AQ_t-1 0.58) |
| SGI: 1.03 (Revenue 3.68b / 3.57b) |
| TATA: -0.10 (NI 443.5m - CFO 1.14b) / TA 6.94b) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at EUR 160.60 with a total of 85,294 shares traded. Over the past week, the price has changed by -5.25%, over one month by +2.82%, over three months by -2.46% and over the past year by +53.26%.
Current recommended Stop Loss: 149.30 (which is 7% or 2.6 ATR below the current price).
Ipsen has no consensus analysts rating.
P/E Trailing = 31.203
P/E Forward = 15.6986
P/S = 3.4909
P/B = 3.2539
P/EG = 0.9935
Revenue TTM = 3.68b EUR
EBIT TTM = 746.3m EUR
EBITDA TTM = 1.10b EUR
Long Term Debt = 834.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 35.3m EUR (from shortTermDebt, last quarter)
Debt = 982.0m EUR (from shortLongTermDebtTotal, last quarter) + Leases 114.9m
Net Debt = -543.5m EUR (calculated: Debt 982.0m - CCE 1.53b)
Enterprise Value = 13.2b EUR (13.7b + Debt 982.0m - CCE 1.53b)
Interest Coverage Ratio = 20.67 (Ebit TTM 746.3m / Interest Expense TTM 36.1m)
EV/FCF = 12.75x (Enterprise Value 13.2b / FCF TTM 1.03b)
FCF Yield = 7.84% (FCF TTM 1.03b / Enterprise Value 13.2b)
FCF Margin = 28.10% (FCF TTM 1.03b / Revenue TTM 3.68b)
Net Margin = 12.07% (Net Income TTM 443.5m / Revenue TTM 3.68b)
Gross Margin = 70.58% ((Revenue TTM 3.68b - Cost of Revenue TTM 1.08b) / Revenue TTM)
Gross Margin QoQ = 59.26% (prev 82.14%)
Tobins Q-Ratio = 1.90 (Enterprise Value 13.2b / Total Assets 6.94b)
Interest Expense / Debt = 3.68% (Interest Expense 36.1m / Debt 982.0m)
Taxrate = 23.11% (133.6m / 578.2m)
NOPAT = 573.9m (EBIT 746.3m * (1 - 23.11%))
Current Ratio = 1.96 (Total Current Assets 2.82b / Total Current Liabilities 1.44b)
Debt / Equity = 0.23 (Debt 982.0m / totalStockholderEquity, last quarter 4.34b)
Debt / EBITDA = -0.49 (Net Debt -543.5m / EBITDA 1.10b)
Debt / FCF = -0.53 (Net Debt -543.5m / FCF TTM 1.03b)
Total Stockholder Equity = 4.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.63% (Net Income 443.5m / Total Assets 6.94b)
RoE = 10.56% (Net Income TTM 443.5m / Total Stockholder Equity 4.20b)
RoCE = 14.83% (EBIT 746.3m / Capital Employed (Equity 4.20b + L.T.Debt 834.2m))
RoIC = 10.73% (NOPAT 573.9m / Invested Capital 5.35b)
WACC = 6.40% (E(13.7b)/V(14.7b) * Re(6.66%) + D(982.0m)/V(14.7b) * Rd(3.68%) * (1-Tc(0.23)))
Discount Rate = 6.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -31.20 | Cagr: -0.62%
[DCF] Terminal Value 77.97% ; FCFF base≈916.9m ; Y1≈1.05b ; Y5≈1.55b
[DCF] Fair Price = 288.3 (EV 23.3b - Net Debt -543.5m = Equity 23.8b / Shares 82.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 93.25 | Revenue CAGR: 5.94% | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=13.78 | Chg30d=+0.81% | Revisions=+0% | GrowthEPS=+14.0% | GrowthRev=+8.6%
EPS next Year (2027-12-31): EPS=13.70 | Chg30d=+1.67% | Revisions=+0% | GrowthEPS=-0.6% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: +0% (up=2, down=2)